X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemotherapy (2) 2
oncology (2) 2
androgens (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
breast cancer (1) 1
breast-cancer (1) 1
cancer (1) 1
carcinoma (1) 1
clinical trials (1) 1
double-blind (1) 1
endometrial cancer (1) 1
endometrial neoplasms - drug therapy (1) 1
endometrial neoplasms - pathology (1) 1
erbb-2 protein (1) 1
expression (1) 1
female (1) 1
gene expression (1) 1
germline brca1/2 mutation (1) 1
homologous recombination (1) 1
hormonal therapy (1) 1
humans (1) 1
identification (1) 1
identification methods (1) 1
immunohistochemistry (1) 1
immunotherapy (1) 1
index medicus (1) 1
life sciences (1) 1
maintenance therapy (1) 1
mechanisms (1) 1
medical prognosis (1) 1
molecular targeted therapy (1) 1
neoplasm recurrence, local (1) 1
olaparib monotherapy (1) 1
ovarian cancer (1) 1
parp inhibitor (1) 1
progesterone (1) 1
prognosis (1) 1
receptor, epidermal growth factor - antagonists & inhibitors (1) 1
resistance (1) 1
rucaparib (1) 1
safety (1) 1
subtypes (1) 1
survival (1) 1
synthetic lethality (1) 1
targeted therapy (1) 1
tor serine-threonine kinases - antagonists & inhibitors (1) 1
tumors (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bulletin du Cancer, ISSN 0007-4551, 12/2017, Volume 104, Issue 12, pp. 1046 - 1053
Endometrial cancer has generally a good prognosis when diagnosed at an early stage, but remains incurable at an advanced stage (recurrent or metastatic) with... 
Chemotherapy | Endometrial cancer | Targeted therapy | Hormonal therapy
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 06/2019, Volume 19, Issue 6, pp. 437 - 446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian... 
Rucaparib | ovarian cancer | PARP inhibitor | synthetic lethality | SAFETY | MECHANISMS | OLAPARIB MONOTHERAPY | MAINTENANCE THERAPY | ONCOLOGY | DOUBLE-BLIND | RESISTANCE | HOMOLOGOUS RECOMBINATION | CARCINOMA | EXPRESSION | GERMLINE BRCA1/2 MUTATION
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.